Efficacy and safety of pyrotinib in combination with albumin-bound paclitaxel for the treatment of HER2-positive advanced breast cancer: A real-world study

被引：2

作者：

Yang, Lixian ^{[1
,3
]}

Zheng, Lei ^{[1
]}

Kong, Fanting ^{[1
]}

Tian, Xinli ^{[2
]}

Zhang, Shiyu ^{[1
]}

Pu, Pengpeng ^{[1
]}

机构：

[1] Xingtai Peoples Hosp, Dept Breast Surg, Xingtai 054000, Hebei, Peoples R China

[2] Xingtai Med Coll, Med Res Ctr, Xingtai 054000, Hebei, Peoples R China

[3] Xingtai Peoples Hosp, Dept Breast Surg, 818 Xiangdu Rd, Xingtai 054000, Hebei, Peoples R China

来源：

ONCOLOGY LETTERS | 2023年 / 26卷 / 01期

关键词：

advanced breast cancer; HER2-positive; trastuzumab; pyrotinib; albumin-bound paclitaxel; NERVOUS-SYSTEM METASTASES; LAPATINIB PLUS CAPECITABINE; RANDOMIZED PHASE-III; TRASTUZUMAB EMTANSINE; BRAIN METASTASES; DOCETAXEL; SURVIVAL; TRIAL; PERTUZUMAB; CHEMOTHERAPY;

D O I：

10.3892/ol.2023.13898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present study aimed to determine the efficacy and safety of pyrotinib in combination with albumin-bound paclitaxel in patients with HER2-positive advanced breast cancer (ABC). A total of 48 patients diagnosed with HER2-positive ABC were included in the present study, and these patients were prescribed a combination of pyrotinib and albumin-bound paclitaxel in routine clinical practice. During a 21-day cycle, the standard dosage of pyrotinib was 400 mg single dose/day, which was administered orally, and 130 mg/m(2)/day albumin-bound paclitaxel on days 1, 8 and 15, which was administered by intravenous drip. The primary efficacy endpoint was progression-free survival (PFS) and the secondary efficacy endpoint was overall response rate (ORR), which was defined as the percentage of patients with complete remission or partial remission. Safety indicators were also observed in the present study. The results of the present study demonstrated that the median PFS (mPFS) was 8.1 months for all patients, ranging from 3.3-10.6 months. Patients receiving pyrotinib as second-line therapy exhibited a longer mPFS of 8.5 months compared with those receiving it as third- or higher-line therapy (mPFS, 5.9 months). In 17 patients with brain metastases, mPFS was 7.3 months, ranging from 4.8-10.1 months. The results of the present study also demonstrated that the ORR for the 48 patients was 33.3%. Notably, diarrhea was the most common grade 3-4 adverse event, occurring in 22.9% of patients, followed by neutropenia (6.3%), leukopenia (4.2%) and anemia (4.2%). Collectively, the results of the present study indicated that pyrotinib-based treatment is effective for patients with HER2(+) ABC, including those who have previously been treated with trastuzumab. Thus, the combination of pyrotinib with albumin-bound paclitaxel is recommended due to high levels of efficacy, convenience and tolerability.

引用

页数：9

共 39 条

[1]

[Anonymous], 2017, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

[2] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[3] Pyrotinib: First Global Approval [J].

Blair, Hannah A. .

DRUGS, 2018, 78 (16) :1751-1755

[4] Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies [J].

Blows, Fiona M. ;

Driver, Kristy E. ;

Schmidt, Marjanka K. ;

Broeks, Annegien ;

van Leeuwen, Flora E. ;

Wesseling, Jelle ;

Cheang, Maggie C. ;

Gelmon, Karen ;

Nielsen, Torsten O. ;

Blomqvist, Carl ;

Heikkila, Paivi ;

Heikkinen, Tuomas ;

Nevanlinna, Heli ;

Akslen, Lars A. ;

Begin, Louis R. ;

Foulkes, William D. ;

Couch, Fergus J. ;

Wang, Xianshu ;

Cafourek, Vicky ;

Olson, Janet E. ;

Baglietto, Laura ;

Giles, Graham G. ;

Severi, Gianluca ;

McLean, Catriona A. ;

Southey, Melissa C. ;

Rakha, Emad ;

Green, Andrew R. ;

Ellis, Ian O. ;

Sherman, Mark E. ;

Lissowska, Jolanta ;

Anderson, William F. ;

Cox, Angela ;

Cross, Simon S. ;

Reed, Malcolm W. R. ;

Provenzano, Elena ;

Dawson, Sarah-Jane ;

Dunning, Alison M. ;

Humphreys, Manjeet ;

Easton, Douglas F. ;

Garcia-Closas, Montserrat ;

Caldas, Carlos ;

Pharoah, Paul D. ;

Huntsman, David .

PLOS MEDICINE, 2010, 7 (05)

[5] Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies [J].

Brosnan, Evelyn M. ;

Anders, Carey K. .

ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (09)

[6] Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER [J].

Brufsky, Adam M. ;

Mayer, Musa ;

Rugo, Hope S. ;

Kaufman, Peter A. ;

Tan-Chiu, Elizabeth ;

Tripathy, Debu ;

Tudor, Iulia Cristina ;

Wang, Lisa I. ;

Brammer, Melissa G. ;

Shing, Mona ;

Yood, Marianne Ulcickas ;

Yardley, Denise A. .

CLINICAL CANCER RESEARCH, 2011, 17 (14) :4834-4843

[7] Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis [J].

Chen, Qitong ;

Ouyang, Dengjie ;

Anwar, Munawar ;

Xie, Ning ;

Wang, Shouman ;

Fan, Peizhi ;

Qian, Liyuan ;

Chen, Gannong ;

Zhou, Enxiang ;

Guo, Lei ;

Gu, Xiaowen ;

Ding, Boni ;

Yang, Xiaohong ;

Liu, Liping ;

Deng, Chao ;

Xiao, Zhi ;

Li, Jing ;

Wang, Yunqi ;

Zeng, Shan ;

Hu, Jinhui ;

Zhou, Wei ;

Qiu, Bo ;

Wang, Zhongming ;

Weng, Jie ;

Liu, Mingwen ;

Li, Yi ;

Tang, Tiegang ;

Wang, Jianguo ;

Zhang, Hui ;

Dai, Bin ;

Tang, Wuping ;

Wu, Tao ;

Xiao, Maoliang ;

Li, Xiantao ;

Liu, Hailong ;

Li, Lai ;

Yi, Wenjun ;

Ouyang, Quchang .

FRONTIERS IN ONCOLOGY, 2020, 10

[8] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].

Cortes, J. ;

Kim, S. -B ;

Chung, W. -P ;

Im, S. -A ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L. -M ;

Petry, V ;

Chung, C. -F ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Huang, C. -S ;

Kim, J. H. ;

Chiu, J. W. Y. ;

Pedrini, J. L. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases [J].

Freedman, Rachel A. ;

Gelman, Rebecca S. ;

Anders, Carey K. ;

Melisko, Michelle E. ;

Parsons, Heather A. ;

Cropp, Anne M. ;

Silvestri, Kelly ;

Cotter, Christine M. ;

Componeschi, Kathryn P. ;

Marte, Juan M. ;

Connolly, Roisin M. ;

Moy, Beverly ;

Van Poznak, Catherine H. ;

Blackwell, Kimberly L. ;

Puhalla, Shannon L. ;

Jankowitz, Rachel C. ;

Smith, Karen L. ;

Ibrahim, Nuhad ;

Moynihan, Timothy J. ;

O'Sullivan, Ciara C. ;

Nangia, Julie ;

Niravath, Polly ;

Tung, Nadine ;

Pohlmann, Paula R. ;

Burns, Robyn ;

Rimawi, Mothaffar F. ;

Krop, Ian E. ;

Wolff, Antonio C. ;

Winer, Eric P. ;

Lin, Nancy U. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1081-+

← 1 2 3 4 →